The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
We focus on a number of topic areas identified by state health policy leaders as important to population health.
The Center for Evidence-based Policy at Oregon Health & Science University is a national leader in evidence-based decision making and policy design.
Keep up with news and updates from the Milbank Memorial Fund. Get the latest from thought leaders, including Christopher F. Koller, president of the Fund.
We publish The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to population health.
As custodians of public funds, state leaders have to determine what to do about high-cost specialty drugs, such as Sovaldi, the expensive and controversial treatment for Hepatitis C. As state officials know only too well, the use of a high-priced drug like Sovaldi could result in an unplanned bottom line increase to already burdened state Medicaid budgets. What should state officials consider when making coverage decisions? What should be the pricing and coverage policies for other high-cost specialty drugs forecasted for release in the coming years?
The MMF has taken on this topic, in response to state interest and questions about high-cost breakthrough drugs. In 2014, the MMF hosted a meeting that enabled researchers and advocates to compare notes about Sovaldi. Also from 2014, read more from Christopher Koller, President of the MMF, about the states and Sovaldi and watch a video on Bio-Pharma Innovations/High Cost Drugs from the Brookings Institute Panel.
Dec 22, 2016
The National Academies of Sciences, Engineering, and Medicine has assembled an ad hoc committee to address patient access to affordable drugs. The Milbank Memorial Fund is one of the sponsors of the committee’s work. The committee will issue a report to address issues such as trends in drug pricing, improved patient access to effective treatments, and innovations that address the needs of … Read more
Sep 21, 2016
The Center for Evidence-based Policy (CEbP) is making progress on SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. Earlier this month, the SMART-D group released a report examining the landscape of Medicaid drug purchasing, specifically focusing on state Medicaid programs’ ability to pursue alternative payment models. The SMART-D Summary Report … Read more
Jun 24, 2016
As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation. Read more
All States and High-Cost Specialty Drugs News